Syqe Medical
Tel Aviv, Israel· Est.
Syqe Medical delivers precise, low‑dose medical cannabis via a patented metered‑dose inhaler for pain and other chronic conditions.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $30M
AI Company Overview
Syqe Medical delivers precise, low‑dose medical cannabis via a patented metered‑dose inhaler for pain and other chronic conditions.
Chronic Neuropathic PainEndometriosisFibromyalgiaCrohn's DiseasePalliative CareNeurologyOncology Symptom ManagementPsychiatryEpilepsy
Technology Platform
Patented metered‑dose inhaler (SyqeAir) combining Electronic Selective‑Dose™, ActiveFlow™, and PulseBreath™ to deliver precise micro‑gram THC doses from full‑spectrum cannabis inflorescence.
Opportunities
Expansion into EU and North American markets, addition of disease‑specific cannabis strains, and potential partnerships with pharma companies for combined drug‑device therapies.
Risk Factors
Regulatory approval variability across jurisdictions, reimbursement uncertainty, and competition from emerging cannabis inhalation technologies.
Competitive Landscape
Few competitors offer metered‑dose cannabis inhalers; Syqe’s patented dose‑control mechanisms and extensive clinical data differentiate it from generic vaping or oil products.